BioWorld Asia

Jan. 22, 2003

View Archived Issues

Future Drugs Could Disrupt Protein Biosynthesis In Cancer

Procognia Closes $4M Round, Acquires Sense Proteomic Ltd.

Cyclacel Starts Phase II Trials Of Small-Molecule CDK Inhibitor

EU Leaders Support Worldwide Ban On Reproductive Cloning

ReNeuron Shares Drop On Failed Phase II Trials Of Lead Product

Second Complication Arises In French Gene Therapy Trial

Xenova Paying $1M For Rights To Two Addiction Vaccines

Adebag Planning Biotechnology Cluster In Southeastern France

Cerep Collaborates With Pfizer On BioPrint Database, Software

Other News To Note

Biolipox Raises EUR21M To Fund Drug Discovery, Development

Swedish drug discovery and development firm Biolipox AB raised €21 million in a second-round financing led by the Paris office of Apax Partners. (BioWorld International) Read More

U.S. Officials Step Up Threats Over European Ban On GM Crops

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery

BioWorld Science

Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...